

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/664,331	
	Filing Date	September 16, 2003	
	First Named Inventor	Laurent HUMEAU	
	Art Unit	1645	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	6	Attorney Docket Number	397272000401


ENCLOSURES (Check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (2 pages) Return Receipt Postcard		
<table border="1"><tr><td>Remarks</td><td>CUSTOMER NO. 25225</td></tr></table>			Remarks	CUSTOMER NO. 25225
Remarks	CUSTOMER NO. 25225			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Brenda J. Wallach - 45,193
Signature	<i>Brenda J Wallach</i>
Date	January <u>30</u> , 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: Jan. 30, 2004Signature: *Diane Blevins*


(Diane Blevins)



PATENT
Docket No. 397272000401

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on January 30, 2004.


Diane Blevins

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Laurent HUMEAU et al.

Serial No.: 10/664,331

Filing Date: September 16, 2003

For: METHODS FOR STABLE
TRANSDUCTION OF CELLS WITH
VIRAL VECTORS

Examiner: Unassigned

Group Art Unit: 1645

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action directed to the related application Serial Number 09/653,088 filed 31 August 2000, and issued 30 September 2003 as U.S. Patent No. 6,627,442, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 397272000401. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 30, 2004

Respectfully submitted,

By: Brenda J. Wallach
Brenda J. Wallach
Reg. No. 45,193
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7961
Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 397272000401

Application Number 10/664,331

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Laurent HUMEAU et al.

Filing Date September 16, 2003

Group Art Unit 1645

Mailing Date: January 30, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	04/1996	5,512,421	Burns et al.	435	320.1	
	2.	04/1998	5,739,018	Miyanohara et al.	435	172.3	
	3.	09/1998	5,814,500	Dietz	435	172.3	
	4.	03/1999	5,885,806	Dropulic et al.	435	91.41	
	5.	05/2000	6,060,317	Malech	435	456	
	6.	01/2000	6,013,516	Verma et al.	435	325	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	7.	11/1996	WO 96/34970	PCT				

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	8.	Anderson, W.F. (1998). "Human gene therapy," <i>Nature</i> 392:25-28.
	9.	Barry, S.C. et al. (2000). "Lentiviral and murine retroviral transduction of T cells for expression of human CD40 ligand" <i>Human Gene Therapy</i> 11:323-332.
	10.	Chinnasamy D. et al. (2000). "Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins" <i>Blood</i> 96(4):1309-1316.
	11.	Costello, E. et al. (2000). "Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors" <i>Gene Therapy</i> 7:596-604.
	12.	Douglas, J. et al. (1999). "Efficient transduction of human lymphocytes and CD34+ cells via human immunodeficiency virus-based gene transfer vectors" <i>Human Gene Therapy</i> 10:935-945.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 397272000401

Application Number 10/664,331

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Laurent HUMEAU et al.

Filing Date September 16, 2003

Group Art Unit 1645

Mailing Date: January 30, 2004

- | | |
|-----|--|
| 13. | Follenzi, A. et al. (2000). "Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences" <i>Nature Genetics</i> 25:217-222. |
| 14. | Han, W. et al. (2000). "A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells" <i>Blood</i> 95:1616-1625. |
| 15. | Haas, D.L. et al. (2000). "Critical factors influencing stable transduction of human CD34+ cells with HIV-1-derived lentiviral vectors" <i>Molecular Therapy</i> 2:71-80. |
| 16. | Hooijberg E. et al. (2000). "NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells" <i>Blood</i> 96:459-466. |
| 17. | Klebba, C. et al. (2000). "Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro" <i>Gene Therapy</i> 7:408-416. |
| 18. | Mitrophanous, K.A. et al. (1999). "Stable gene transfer to the nervous system using a non-primate lentiviral vector," <i>Gene Therapy</i> 6:1808-1818. |
| 19. | Movassagh, M. et al. (2000). "Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection" <i>Human Gene Therapy</i> 11:1189-1200. |
| 20. | Movassagh, M. et al. (1999). "High level of retrovirus-mediated gene transfer into dendritic cells derived from cord blood and mobilized peripheral blood CD34+ cells," <i>Human Gene Therapy</i> 10(2):175-187. |
| 21. | Naldini, L. et al. (1996). "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector," <i>Science</i> 272:263-267. |
| 22. | Onodera, M. et al. (1998). "Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency" <i>Blood</i> 91:30-36. |
| 23. | Quinn, E.R. et al. (1998). "T cell activation modulates retrovirus-mediated gene expression," <i>Human Gene Therapy</i> 9(10):1457-1467. |
| 24. | Richardson, J.H. et al. (1998). "Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector," <i>Gene Therapy</i> 5:635-644. |
| 25. | St. Croix, B. et al. (2000). "Genes expressed in human tumor endothelium" <i>Science</i> 289:1197-1202. |
| 26. | Uchida, N. et al. (1998). "HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells," <i>PNAS USA</i> 95(20):11939-11944. |
| 27. | Unutmaz, D. et al. (1999). "Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes" <i>J. Exp. Med.</i> 11:1735-1746. |
| 28. | Zennou, V. et al. (2000). "HIV-1 genome nuclear import is mediated by a central DNA flap" <i>Cell</i> 101:173-185. |
| | |
| | |
| | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.